TABLE 4.
Features admission and outcomes by immunosuppression strategy
| Baseline characteristics | Total N = 29 | Minimization N = 6 | Cyclosporin N = 23 | P | ||
|---|---|---|---|---|---|---|
| Age, m (IQR) | 66 (59-72) | 66 (59-71) | 65 (56-73) | .845 | ||
| Female Gender, n (%) | 12 (41.4) | 4 (66.7) | 8 (34.8) | .198 | ||
| Transplantation time mo., m(IQR) | 99.22 (26-171) | 99 (26.6-159) | 102 (27.14-171) | .862 | ||
| Risk factors > 3, n (%) | 18 (62.1) | 2 (33.3) | 16 (69.6) | .164 | ||
| Admission characteristics | ||||||
| Symptoms days, m (IQR) | 5 (2.5-7) | 4 (1.5-4.75) | 6 (3-7) | .192 | ||
| Dyspnea, n (%) | 12 (44.4) | 2 (33.3) | 13 (52.2) | .361 | ||
| X-ray abnormalities | No infiltrates, (%) | 11 (37.9) | 4 (66.75) | 7 (29.2) | .344 | |
| BPS, n (%) | 9 (31) | 1 (16.7) | 8 (34.8) | |||
| Oxygen requirement | Basal n, (%) | 22 (75.9) | 5 (83.3) | 17 (73) | .642 | |
| VM/R/CPAP n, (%) | 3 (10.3) | 0 (0) | 3 (13) | |||
| D dimer (ng/mL), m (IQR) | 1429 (754-2358) | 1066 (844-1042) | 1627 (602-2691) | .146 | ||
| Ferritin (ng/mL), m (IQR) | 647 (348-1682) | 554 (67-2764) | 725(403-1684) | .380 | ||
| LDH, IU/l, m (IQR) | 488 (360-712) | 443 (399-535) | 584 (330-719) | .742 | ||
| CKD-EPI, mL/min, m (IQR) | 25.0 (16.75-45) | 41. (19-80.5) | 25 (16.43) | .212 | ||
| AKI, n (%) | 14 (48.2) | 1 (16.7) | 13 (56.5) | .169 | ||
| Treatments | ||||||
| Hydroxychloroquine | 27 (93.1) | 5 (83.3) | 22 (95.7) | .377 | ||
| Steroids bolus, n (%) | 18 (62.1) | 3 (50) | 15 (62.5) | .646 | ||
| Cumulative steroid doses, mg, m (IQR) | 735 (375-1260) | 1033 (125-1250) | 735 (375-1455) | 1.000 | ||
| Tocilizumab, n (%) | 9 (31) | 2 (33.3) | 7 (30.4) | 1.000 | ||
| IG, n (%) | 8 (27.6) | 3 (50) | 5 (21.5) | .300 | ||
| Anticoagulation, n (%) | 24 (82.2) | 3 (50) | 21 (91.3) | .046 | ||
| Outcomes | ||||||
| Radiologic worsening, n (%) | 19 (65.5) | 5 (83) | 14 (60.9) | .633 | ||
| Analytical worsening, n (%) | 16 (55.2) | 6 (100) | 10 (43.5) | .017 | ||
| Ferritin max, ng/mL, m (IQR) | 1226 (496-2027) | 2090 (1190-3482) | 923 (443-1887) | .140 | ||
| LDH max, IU/l m (IQR) | 713(457-981) | 1167 (768-1466) | 645 (448-829) | .021 | ||
| AKI recovered, n (%) | 10 (34.48) | 0 (0) | 10 (43.4) | .145 | ||
| AKI with HD, n (%) | 3 (10.3) | 0(0) | 3 (13) | .145 | ||
| Oxygen requirement increase | Yes, n (%) | 16 (55.2) | 5 (83.3) | 11 (47.8) | .119 | |
| Day, m (IQR) | 4 (2-7) | 8 (3.5-5) | 3.5 (5.5-10) | .006 | ||
| Max oxygen requirement | Basal, n (%) | 11 (37.9) | 1 (16.7) | 10 (43.5) | .035 | |
| NG, n (%) | 9 (31) | 1 (16.7) | 8 (34.8) | |||
| IMV, n (%) | 5 (17.2) | 1 (16.7) | 4 (17.4) | 1.000 | ||
| Death, n (%) | 6 (20.7) | 3 (50) | 3 (13) | .047 | ||
| Discharge, n (%) | 23 (79.3) | 3 (50) | 20 (87) | |||
Abbreviations: AKI, acute kidney injury; BPS, bilateral patchy shadowing; max, maximum; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; CPAP, continuous positive airway pressure; HD, hemodialysis, IG, immunoglobulins; IMV, invasive mechanical ventilation; IQR, interquartile range; m, median; NG, nasal glasses (2-3 lpm); R, reservoir (15 lpm); VM, venturimask (8-10 lpm).
Actual status (May 19, 2020), Units: D dimer (ng/mL): normal range < 500 ng/mL, ferritin (ng/mL) normal range 30-350 ng/mL, LDH, lactate dehydrogenase (UL/l), normal range 240-480 U/ I. Day, day of oxygen requirement increase from admission.